Abstract Submissions

Abstract submissions are now closed

Submission guidelines

Delegates who would like to present their work at the meeting, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee.

Abstracts are accepted on a wide range of themes including immune regulation of inflammation and cancer, the microbiota and regulation of inflammation, cytokine regulation of cellular metabolism, cytokine signaling and epigenetics, interferons: regulators of immunity and inflammation, innate and adaptive immune mechanisms of host defense, cytokines and metabolic diseases, and other topics.

Please refer to the instructions here below so as to ensure a smooth and successful abstract submission.

The corresponding topic must be selected to ensure correct scoring of the abstract. The content of the abstract must be topic related. The papers will be peer-reviewed and selected for poster or oral presentation.

A paper should not be submitted to the 4th Annual Meeting of the International Cytokine and Interferon Society if the full paper has been already published.

For standardization, the acceptable length of the abstract is of maximum 3’600 characters and 45 lines. This includes the author’s details, titles and non-visible characters, such as spaces and line breaks.

Abstracts can be saved in “Draft” status to be re-edited and modified until the submission deadline (Wednesday 1st June 2016, 23:59 CET). Therefore, the submitter will be required to create a user account.

Abstracts fulfilling all criteria can be saved in “Final submission” status. Only abstracts in “Final submission” status will be regarded as successfully submitted and considered for the meeting. The submitted / draft abstracts cannot be edited after the submission deadline (Wednesday 1st June 2016, 23:59 CET)

The abstract should be structured into the following sections:

• A title which clearly indicates the nature of the investigation.
• Introduction should contain 1-2 sentences that clearly indicate the scientific question of the study and its clinical (or other) importance.
• Methods should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study.
• Results should contain objective data to answer the scientific question(s).
• Conclusions should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.
• No tables or figures can be included in the abstract.

Conflict of interest: It is the intent of Cytokines 2016 to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during abstract submission.

Abbreviations should be indicated in parentheses following their first mention in the text. Trade names cannot be mentioned in the title. However, trade names in brackets will be accepted in the body of the text.

The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Programme Committee. Registration fees will not be waived.

The presenting author of the abstract must be registered at the meeting within 14 days of confirmation of abstract acceptance (the author will benefit from early bird registration fee).

Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done. No changes can be made to the abstract after the submission deadline.

After the submission

The reviewers will judge the abstracts according to scientific or clinical value, relevance to Cytokines 2016, conclusions confirmed by objective results, objectivity of statements, originality of work and overall impression.

The submitting authors will be notified by early July at the email address provided during submission whether their abstract has been accepted.

If you need to withdraw your abstract a written statement, reflecting the reasons of this decision must be sent to cytokines.abs@mci-group.com no later than 15 July 2016.

Presentation of abstracts

Abstracts can be accepted either as poster or oral communication.

If your abstract is accepted as a poster, you will be requested to be available for discussion during the corresponding poster viewing session. Details on poster format and full presentation guidelines will be included in the notification letter and posted on the meeting website.

Publication

Accepted abstracts will be available on the Cytokines 2016 website, about one month prior to the meeting and they will be published in the electronic version of abstract book included in the meeting documents provided to registered delegates.

Contacts

For any further enquiries, please contact the Cytokines 2016 Abstract Handling Team at cytokines.abs@mci-group.com